Literature DB >> 9510315

Perianal infections in patients with leukemia: importance of the course of neutrophil count.

Y Büyükaşik1, O I Ozcebe, N Sayinalp, I C Haznedaroğlu, O O Altundağ, O Ozdemir, S Dündar.   

Abstract

PURPOSE: This study was performed to evaluate relations among neutrophil count (including its course), type of lesion, treatment, and prognosis in patients with leukemia and perianal infection.
METHODS: Medical records of patients with acute and chronic leukemia who were followed during the last five years were reviewed retrospectively.
RESULTS: The incidence of perianal infections was found to be 7.3 percent in 259 patients with acute leukemia. Only 1 of 108 patients with chronic leukemia suffered from this problem. Twenty percent of all patients with this complication died as a result of sepsis. Perianal abscess was the sole and obligatory indication for surgical treatment in our patients. There were ten patients in each treatment group. The operative group had better results (9 cures, 1 complication vs. 3 cures, 7 complications). However, median neutrophil count at diagnosis was notably higher in the operative group 1,280/mm3 vs. 96/mm3; P = 0.075). Also, significantly more frequent abscess formations and, consequently, operative treatments were performed in patients with a period of normal neutrophil counts during the infection compared with continuously neutropenic patients (9 operative, 4 nonoperative vs. 1 operative, 6 nonoperative; P = 0.057). Ten cures, three complications vs. two cures, five complications (3 mortalities) were present in patients with and without normal neutrophil counts, respectively (P = 0.062). When only severely neutropenic patients were considered, four patients in the surgery group had normal neutrophil counts before or shortly after surgery. However, only two of eight patients with perianal cellulitis had normal counts during full-course infection (P = 0.06).
CONCLUSIONS: The course of the neutrophil count during infection was an important factor affecting the perianal lesion, and indirectly, choice of treatment and prognosis. A period of normal counts during infection usually led to well bordered and fluctuant lesions, and the prognosis was acceptable with operative treatment. However, continuously neutropenic patients developed nonfluctuating indurations. We found disappointing results with nonoperative treatment of such patients. In all studies, regarding treatment of perianal infections in neutropenic patients, the course of the neutrophil count and indications for surgery should be clarified to get reliable results.

Entities:  

Mesh:

Year:  1998        PMID: 9510315     DOI: 10.1007/BF02236900

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  13 in total

1.  Increased risk of diabetes following perianal abscess: a population-based follow-up study.

Authors:  Po-Li Wei; Joseph J Keller; Li-Jen Kuo; Herng-Ching Lin
Journal:  Int J Colorectal Dis       Date:  2012-06-23       Impact factor: 2.571

Review 2.  Evaluation and management of perianal abscess and anal fistula: a consensus statement developed by the Italian Society of Colorectal Surgery (SICCR).

Authors:  A Amato; C Bottini; P De Nardi; P Giamundo; A Lauretta; A Realis Luc; G Tegon; R J Nicholls
Journal:  Tech Coloproctol       Date:  2015-09-16       Impact factor: 3.781

3.  Evaluation and management of perianal abscess and anal fistula: SICCR position statement.

Authors:  A Amato; C Bottini; P De Nardi; P Giamundo; A Lauretta; A Realis Luc; V Piloni
Journal:  Tech Coloproctol       Date:  2020-01-23       Impact factor: 3.781

4.  A perianal presentation of myeloid sarcoma.

Authors:  Navraj S Nagra; Emilio Lozano; Elizabeth Soilleux; Pepe Mullerat
Journal:  BMJ Case Rep       Date:  2015-05-12

Review 5.  Anorectal emergencies: WSES-AAST guidelines.

Authors:  Antonio Tarasconi; Gennaro Perrone; Justin Davies; Raul Coimbra; Ernest Moore; Francesco Azzaroli; Hariscine Abongwa; Belinda De Simone; Gaetano Gallo; Giorgio Rossi; Fikri Abu-Zidan; Vanni Agnoletti; Gianluigi de'Angelis; Nicola de'Angelis; Luca Ansaloni; Gian Luca Baiocchi; Paolo Carcoforo; Marco Ceresoli; Alain Chichom-Mefire; Salomone Di Saverio; Federica Gaiani; Mario Giuffrida; Andreas Hecker; Kenji Inaba; Michael Kelly; Andrew Kirkpatrick; Yoram Kluger; Ari Leppäniemi; Andrey Litvin; Carlos Ordoñez; Vittoria Pattonieri; Andrew Peitzman; Manos Pikoulis; Boris Sakakushev; Massimo Sartelli; Vishal Shelat; Edward Tan; Mario Testini; George Velmahos; Imtiaz Wani; Dieter Weber; Walter Biffl; Federico Coccolini; Fausto Catena
Journal:  World J Emerg Surg       Date:  2021-09-16       Impact factor: 5.469

Review 6.  Management of acute perianal sepsis in neutropenic patients with hematological malignancy.

Authors:  B Baker; M Al-Salman; F Daoud
Journal:  Tech Coloproctol       Date:  2013-11-26       Impact factor: 3.781

Review 7.  Gastrointestinal Surgical Emergencies in the Neutropenic Immunocompromised Patient.

Authors:  Michael G White; Ryan B Morgan; Michael W Drazer; Oliver S Eng
Journal:  J Gastrointest Surg       Date:  2021-09-10       Impact factor: 3.452

8.  Anorectal Abscess in a Patient with Neutropenia and Refractory Acute Myeloid Leukemia: To Operate or not to Operate?

Authors:  Masami Ohzu; Hitomi Takazawa; Satomi Furukawa; Yukiko Komeno
Journal:  Am J Case Rep       Date:  2021-07-04

9.  Clinical and microbiological characteristics of perianal infections in adult patients with acute leukemia.

Authors:  Chien-Yuan Chen; Aristine Cheng; Shang-Yi Huang; Wang-Huei Sheng; Jia-Hau Liu; Bo-Sheng Ko; Ming Yao; Wen-Chien Chou; Hui-Chi Lin; Yee-Chun Chen; Woei Tsay; Jih-Luh Tang; Shan-Chwen Chang; Hwei-Fang Tien
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Anorectal Complications During Neutropenic Period in Patients with Hematologic Diseases.

Authors:  Soner Solmaz; Aslı Korur; Çiğdem Gereklioğlu; Süheyl Asma; Nurhilal Büyükkurt; Mutlu Kasar; Mahmut Yeral; İlknur Kozanoğlu; Can Boğa; Hakan Ozdoğu
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-03-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.